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Background. Loss of muscle mass and strength with ageing is a major cause for falls, disability, and morbidity in 
older people. Previous studies have found that angiotensin-converting enzyme inhibitors (ACEi) may improve physical 
function in older people. It is unclear whether ACEi provide additional benefit when added to a standard exercise training 
program. We examined the effects of ACEi therapy on physical function in older people undergoing exercise training.
Methods. Community-dwelling people aged ≥65 years with functional impairment were recruited through general 
(family) practices. All participants received progressive exercise training. Participants were randomized to receive either 
4 mg perindopril or matching placebo daily for 20 weeks. The primary outcome was between-group change in 6-minute 
walk distance from baseline to 20 weeks. Secondary outcomes included changes in Short Physical Performance Battery, 
handgrip and quadriceps strength, self-reported quality of life using the EQ-5D, and functional impairment measured 
using the Functional Limitations Profile.
Results. A total of 170 participants (n = 86 perindopril, n = 84 placebo) were randomized. Mean age was 75.7 (stand-
ard deviation [SD] 6.8) years. Baseline 6-minute walk distance was 306 m (SD 99). Both groups increased their walk 
distance (by 29.6 m perindopril, 36.4 m placebo group) at 20 weeks, but there was no statistically significant treatment 
effect between groups (−8.6m [95% confidence interval: −30.1, 12.9], p =  .43). No statistically significant treatment 
effects were observed between groups for the secondary outcomes. Adverse events leading to withdrawal were few (n = 0 
perindopril, n = 4 placebo).
Interpretation. ACE inhibitors did not enhance the effect of exercise training on physical function in functionally 
impaired older people.
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THE age-related loss of skeletal muscle mass, quality, and strength (sarcopenia) is a major contributor to loss 
of mobility and independence among older people (1). To 
date the mainstay in attempting to counter the effects of sar-
copenia has been progressive exercise training. However, 
older people have a finite capacity for exercise participation 
and are more likely to need to interrupt an exercise program 
because of ill health (2). Although older exercisers experi-
ence a markedly slower rate of physical functional decline 
than their less active counterparts, year-on-year functional 
decline occurs even in older people who meet target exer-
cise recommendations (3). Identifying interventions that 
improve physical function will help maximize healthy age-
ing in our growing older population, a global public health 
imperative (4).
Angiotensin-converting enzyme inhibitors (ACEi) may 
have the potential to improve physical function and improve 
the response to exercise training. Younger people with the II 
genotype of the ACE gene have low serum ACE levels. This 
genotype displays not only better endurance performance 
but also greater improvements in endurance following 
training (5). It is therefore possible that pharmacologically 
reducing serum ACE levels with ACEi and combining this 
with exercise might enhance the beneficial effects of exer-
cise training. We have previously shown that ACEi pro-
duced a significant improvement in 6-minute walk distance 
(6MWD) in functionally impaired older people (mean age 
79 years) who did not have heart failure (6). The magni-
tude of improvement in 6MWD as a test of physical func-
tion was comparable with that reported after 6 months of 
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exercise training (7). More recently, Buford et al. (8) found 
that older people who were taking ACEi for clinical indi-
cations had a greater functional response to exercise than 
those not taking ACEi. No randomized studies have been 
conducted to examine the effect of adding ACEi to exer-
cise training on physical function in humans. Observational 
studies have shown that the use of ACE inhibitors is associ-
ated with a slower decline in muscle mass, muscle strength, 
and walking speed in older people suggesting that there 
may be a direct effect on skeletal muscle (9,10). It is possi-
ble that exercise training and ACEi target different compo-
nents of muscle function producing an additive effect. This 
trial aimed to establish whether the known beneficial effect 
of exercise training could be amplified by concomitant ACE 
inhibition in older people with functional impairment.
Methods
This was a double-blind randomized controlled parallel 
group trial approved by the East of Scotland Research Ethics 
Committee (09/S0501/48). It conformed to the principles of 
the Declaration of Helsinki. The trial was registered at www.
controlled-trials.com (ISRCTN67166885; full study protocol 
can be accessed as an online Supplementary file). Between 
March 2010 and February 2012, community-dwelling people 
aged ≥65 years were recruited on a rolling basis. Following 
a preliminary general (family) practitioner database search 
through the Eastern Node of the Scottish Primary Care 
Research Network, letters of invitation were sent to potential 
participants. Potential participants attending secondary care 
medicine for the elderly services in Tayside and Fife were also 
sent letters of invitation. The research team then contacted 
those who expressed an interest in taking part for a screen-
ing visit if they reported mobility impairment requiring the 
use of a walking aid and/or dependence in functional activi-
ties of daily living (transfers, stairs, washing, or dressing). 
Following written informed consent, people aged ≥ 65 years 
with a Short Physical Performance Battery (SPPB) score ≤ 
10 were included. We excluded those already receiving ACEi 
or angiotensin receptor blocker; those with contraindications 
to ACEi (significant aortic outflow obstruction with pressure 
gradient > 30 mmHg, estimated glomerular filtration rate < 
30 mL/min/1.73 m2 by MDRD4 equation (11), systolic blood 
pressure < 90 mmHg); those with a clinical diagnosis of heart 
failure according to the European Society of Cardiology 
guidelines (12) or left ventricular systolic dysfunction on 
echocardiography; those who regularly participated in exer-
cise training; those with moderate to severe cognitive impair-
ment (Mini Mental State Examination < 20/30); and those who 
were wheelchair bound. A diagnosis of hypertension or use of 
antihypertensive medications was not an exclusion criterion.
Interventions
Participants were randomized (1:1 allocation ratio, no 
stratification) to receive either perindopril or matching 
placebo for 20 weeks. Computer-generated randomization 
was performed by Tayside Pharmaceuticals who dispensed 
the trial medication in identical, sequentially numbered 
bottles. Treatment allocation was concealed to all others 
involved in the study. A total of 86 participants were ran-
domized to the perindopril group and 84 to the placebo 
group. The starting dose of perindopril 2 mg daily was 
commenced simultaneously with exercise training. This 
was uptitrated to 4 mg after 2 weeks if tolerated. The pla-
cebo group also underwent a “mock” uptitration. Although 
we anticipate the effect is generic to ACEi, perindopril was 
chosen as it is well tolerated in older people and because 
of existing evidence that 20 weeks of perindopril therapy 
improved 6-minute walking distance in older people (6).
All participants received a 20 week duration progressive 
exercise training program previously shown to be accept-
able to very old people with multimorbidity (13). This 
comprised 10 weeks of supervised hospital-based training 
followed by 10 weeks of unsupervised home-based training. 
This strategy was adopted because group exercise therapy 
is the standard approach in clinical practice, but evidence 
suggests that adherence to exercise in older people is higher 
with home-based training (14). We used a combination of 
exercise strategies for both efficiency and to achieve maxi-
mal benefit.
Phase I: Supervised hospital-based training twice per 
week for 10 weeks.—Individually tailored, twice-weekly, 
hospital-based group outpatient progressive exercise train-
ing sessions were held (group sizes of 4–10). Exercises 
comprised a mixture of intermittent functional exercise 
(marching, stepping on stairs, shuttle walking, sit-to-
stands, wall presses), and strength and balance (heel and 
toe touch, heel and toe raise, dynamic leg swing, tandem 
walk) training, with resistance provided by the use of 
elasticated resistance bands (elbow flexion and extension; 
shoulder flexion, extension, and abduction; punching; hip 
extension and abduction; knee flexion). Baseline exercise 
level was assessed on information gained during the first-
group session and from participants’ personal exercise log-
book. The duration and intensity of exercise was tailored 
accordingly. Participants were commenced on the highest 
band resistance level that allowed them to complete at least 
eight repetitions. For the functional and balance exercises, 
the number of repetitions they could achieve at their fastest 
pace was taken as their baseline, aiming for a minimum of 
10 repetitions. Group-guided discussion sessions based on 
cognitive and behavioral techniques were incorporated into 
this phase to achieve behavior change. Participants were 
given a structured educational package reinforcing the top-
ics covered (available on request from authors), and they 
were encouraged to set realistic goals for their exercise pro-
gram. The duration and intensity of the exercise was gradu-
ally increased, and participants were encouraged to increase 
these by 10% from baseline each week. Resistance exercise 
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was commenced at 8–10 repetitions gradually increasing to 
two sets of 10 repetitions at the end of 10 weeks. Individual 
ability was assessed on an ongoing basis, and participants 
who achieved their targets early were commenced on a 
higher level of band resistance. Balance exercises were 
carried out at between 10 and 20 repetitions with the main 
focus being on the quality of movement. Participants were 
encouraged to record the number of repetitions of exercise 
in their logbook for personal reference only. Participants 
were also encouraged to continue their exercises at home in 
between the exercise classes.
Phase II: Unsupervised home-based exercise training 
for 10 weeks.—Participants used the daily-activity self-
monitoring log to record goals, strategies for dealing with 
setbacks, and estimates of time spent engaging in exercise. 
The physiotherapist telephoned participants weekly for 4 
weeks, and then fortnightly. Such a strategy is an effective 
alternative to face-to-face contact with older people, giv-
ing equally good adherence for endurance exercise over 
extended periods (15). All information on progression or 
maintenance of the exercises was reported subjectively via 
telephone consultation. For those who had plateaued dur-
ing the first 10 weeks, maintenance of their exercise levels 
was encouraged, and for those who had not achieved their 
personal goals, further guidance on progression was given, 
and resistance levels were increased as they progressed 
This period of telephone review was mainly motivational, 
encouraging regular exercise through home exercise and 
seeking out local exercise programs that would be suit-
able to maintain good exercise adherence for the future. 
Participants were asked to follow the exercise strategy on 
at least 2 days per week with encouragement to increase the 
number of days they performed these.
Outcomes
Outcomes were assessed at baseline and again at 10 and 
20 weeks after randomization by a single researcher blind 
to treatment allocation.
Primary outcome.—The primary outcome was the 
change from baseline in 6-minute walking distance at 20 
weeks. This is a validated, safe, and reliable measure of 
physical functional status and exercise capacity in older 
people (16,17).
Secondary outcomes.—Secondary outcomes include the 
following:
1. Physical performance
 SPPB: This assesses lower extremity function and has 
been shown to predict subsequent disability, institution-
alization, and mortality (18) and is responsive to the 
effects of exercise in older people (19).
 Quadriceps strength: This was measured using a hand-
held dynamometer (model 01163 Lafayette Instrument 
Company, Lafayette, Indiana). The device has good cor-
relation with the gold standard of Biodex dynamometry 
in older people (20).
 Grip strength: Upper limb muscle strength was measured 
using a handheld dynamometer (T.K.K 5401 Grip D). 
This measure is sensitive to change in older people.
2. Health-related quality of life and self-reported func-
tion—EQ-5D and Functional Limitation Profile (FLP):
 The EQ-5D provides a brief measure of health status in 
a single index score (21). The FLP (22), a modified ver-
sion of the Sickness Impact Profile, is a generic health 
status measure of change in behavior as a consequence of 
illness.
 Baseline demographics were collected. The Scottish 
Index of Multiple Deprivation was used to derive quin-
tiles of deprivation based on post code (23). Serum urea, 
creatinine, and potassium were measured, and blood 
pressure was recorded at each visit. Adverse events were 
recorded at each visit.
Sample Size Calculation and Power
Our previous data in a similar population showed a mean 
improvement in 6MWD of 31 m with a standard devia-
tion of change of 50 m (6). We powered our trial around an 
improvement in 6MWD of 22.5m in the ACEi group (over 
and above the anticipated increase with exercise training). 
This magnitude of improvement is of clinical significance 
(24), is realistic, and if observed would be sufficiently com-
pelling to alter clinical practice. To detect this between-
group difference with 80% power at alpha = 0.05 using a 
two-sample t-test of the change over baseline requires 158 
participants (79 per group). Anticipating a 15% dropout 
rate, we planned to recruit 186 participants. However, as 
dropout rate was lower but recruitment was slower than 
anticipated, a total of 170 participants were randomized.
Statistical Analysis
Statistical analyses were preplanned and performed 
using SAS v9.2. The analysis plan was finalized, and analy-
sis was performed prior to breaking the treatment code. All 
outcomes were summarized at baseline, 10, and 20 weeks, 
and changes over baseline were estimated and tested using 
paired t-tests. Between-group differences in outcomes were 
analyzed using analysis of covariance, with the change over 
baseline as the response variable, and with treatment group, 
the baseline value of the outcome and sex as predictor vari-
ables. Sex was included as a predictor in all regression mod-
els at the request of the Data Monitoring Committee due to 
an imbalance between groups.
Analyses were conducted using the intention to treat prin-
ciple, with individuals analyzed according to randomized 
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group, regardless of compliance with study medication or 
procedures. Per-protocol analyses were also carried out 
based on a population who took at least 80% of expected 
study medication, attended all study visits, and participated 
in at least 80% of exercise classes (supervised hospital-based 
training only). To assess the impact of missing data, the pri-
mary analysis was repeated using multiple imputations. Ten 
imputations were run and combined for missing 6MWD at 
20 weeks. Baseline 6MWD, treatment group, age, sex, and 
deprivation quintile were used to generate imputed values. 
Repeated measures analyses of all outcomes at 10 and 20 
weeks were also performed as secondary analyses. A two-
sided p value of <.05 was taken as significant for all analy-
ses; correction for multiple analyses was not performed. 
Prespecified subgroup analysis was performed for change 
in 6MWD at 20 weeks for subgroups defined at baseline 
by the presence/absence of hypertension. In addition, a fur-
ther subgroup analysis for sex was carried out to investigate 
whether the intervention effects were different between the 
males and females in terms of the primary outcome.
Results
A total of 10,900 potential participants were identified 
based on a preliminary screen excluding those less than 
65  years, those already taking ACE inhibitors, and those 
with a diagnosis of heart failure. These potential partici-
pants were contacted by letter, and 92% (10,057/10,900) 
failed to reply. Following a brief telephone screen, 190/843 
of responders attended a screening visit. One hundred and 
seventy participants were randomized, and 160/170 (94%) 
participants completed the study. Figure  1 shows partici-
pant flow through the trial. Table 1 shows the baseline char-
acteristics of the two groups. Table 2 displays summaries of 
changes from baseline at 10 and 20 weeks, and estimated 
treatment effect based on analysis of covariance.
Primary Outcome
Mean baseline 6MWD was 306 m and was significantly 
increased from baseline by 30.5 m (95% confidence interval 
[95% CI]: 20.9, 40.1; p < .001) at 10 weeks and by 32.9 
m (95% CI: 22.1, 43.7; p < .001) at 20 weeks in the over-
all population recruited. However, there was no evidence 
of a treatment effect between the perindopril and placebo 
groups at 20 weeks (estimated difference, −8.6m [95% CI: 
−30.1, 12.9], p = .43; Table 2). Additional analyses of the 
treatment effect estimated using repeated measures anal-
yses (−8.4 [95% CI: −28.7, 11.9], p = .42), per protocol 
analysis (−5.3 [95% CI: −32.3, 21.7], p = .70), and the pri-
mary analysis with multiple imputation for missing data at 
20 weeks (−10.3 [95% CI: – 31.0, 10.4], p = .33) comparing 
the perindopril and placebo groups were similar to the main 
analyses. Subgroup analysis showed no difference in treat-
ment effect between those and without hypertension (−17.6 
m vs −4.2 m; p = .58). A subgroup analysis by sex suggests 
no difference in terms of the primary outcome between 
males and females (males: −11.1 [95% CI: −44.7, 22.5], 
p = .52; females: −6.9 [95% CI: 35.1, 21.4], p = .63; p for 
interaction = 0.85).
Secondary Outcomes
No statistically significant treatment effect differences 
were observed between perindopril and placebo groups 
for quadriceps or grip strength, EQ-5D score or Visual 
Analogue Scale, SPPB score, or FLP score at 10 or 20 
weeks (Table 2).
Other Measures
As expected, the mean blood pressure at 20 weeks in the 
perindopril group was significantly lower by 6.5 mmHg, 
(95%CI: 1.6, 11.5; p = .01) systolic and by 3.9 mmHg (95% 
CI: 1.0, 6.8; p = .009) diastolic compared with the placebo 
group. Two participants had antihypertensive medication 
commenced during the study, two had an additional antihy-
pertensive agent added, and two had one antihypertensive 
medication stopped. No participant was commenced on an 
ACEi out with the study. Mean creatinine and potassium 
levels were unchanged throughout the study, with no evi-
dence of any differences between perindopril or placebo 
groups.
Adverse Events
There were no suspected unexpected serious adverse 
reactions, and no participant died during the trial. As 
expected in this older population with multimorbidity, 
adverse event rates were high, with 88% of participants in 
the safety population (randomized subjects who took at least 
one dose of study medication) reporting at least one adverse 
event (Table 3). Four adverse events led to withdrawal in the 
placebo group (Figure 1; n = 1 worsening of Parkinson’s 
disease, n = 1 exacerbation of chronic obstructive pulmo-
nary disease, n = 1 cerebral hemorrhage, n = 1 stroke). One 
participant was withdrawn on the advice of the investiga-
tor (Figure 1) as the researcher felt that the participant had 
not retained information about the study and therefore was 
unable to continue in the study with full informed consent.
Serious adverse events resulting in admission to hos-
pital were seen in 7 participants in the perindopril group 
(2 collapse; 1 vasovagal syncope following diarrhea and 
vomiting; 2 falls of which one had a fracture; 1 exacerba-
tion of chronic obstructive pulmonary disease; 1 bleeding 
following elective surgery) and 10 participants in the pla-
cebo group (1 fall; 1 participant had back pain, a fall with a 
fracture and a deep vein thrombus; 2 cerebral vascular acci-
dent of whom one was also admitted for abdominal pain; 
1 hernia and abdominal pain; 1 spinal nerve compression; 
1 corneal ulcer; 1 chest pain; 1 acute pulmonary edema; 1 
exacerbation of cryptogenic organizing pneumonia)
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Adherence With Interventions
Six participants declined to take study medication follow-
ing randomization, and 45/164 (27%) participants discon-
tinued study medication (33% and 22% in the perindopril 
and placebo groups, respectively) after commencing. The 
median [interquartile range] adherence estimated by tablet 
counting in people continuing medication was 99% [95%, 
101%] for the perindopril group and 99% [98%, 101%] 
for the placebo group. Attendance at supervised exercise 
sessions was good, with a median [interquartile range] 
attendance of 18 [16, 20] for both groups out of 20 possible 
sessions. Adherence to exercise during 11–20 weeks were 
not recorded as the only basis for this would have been self-
report from participants, which is known to be inaccurate.
Discussion
We found no evidence that the perindopril enhanced the 
effect of exercise training on physical function in a group 
of functionally impaired older people without heart failure. 
The effect of exercise was apparent as both groups increased 
their mean 6MWD by around 30 m from baseline, similar 
to that reported in other studies of exercise training in older 
people (7,25). This was achieved by 10 weeks with little 
further improvement. Similarly, there were no statistically 
Init_ial populat_ion screen by age, ACEi use and heart failure
Invitat_ion let_ters sent to potent_ial eligible (n=10,900) 
Primary Care (n=10767) 
Medicine for Elderly (n=133) 
Invited to screening visit 
(n=190) 
Withdrawals (n=7)
Adverse event (n=4) 
Unwilling to cont_inue in study 
(n=1) 
Withdrew consent (n=2) 
Withdrawn on the advice of 
invest_igator (=0) 
Telephone screening 
(n=843) 
Randomised
(n=170) 
Allocated to placebo 
(n=84) 
Allocated to perindopril
(n=86) 
Completed 10 weeks
(n=83/86, 96.5%) 
Completed 20 weeks
(n=83/86, 96.5%) 
Completed 10 weeks
(n=77/84, 91.7%) 
Completed 20 weeks
(n=77/84, 91.7%) 
Failed screening (n=20)
No ADL problems (n=12) Serum 
Potassium >5.0mmol/L (n=4) 
Signiﬁcant aort_ic out_flow obstruct_ion 
(n=1) 
Undiagnosed heart failure (n=2) 
MMSE <20/30 (n=1) 
No reply (n=10057)
Excluded (n=653)
Inclusion criteria not 
met 
Withdrawals (n=3)
Adverse event (n=0) 
Unwilling to cont_inue in study 
(n=0) 
Withdrew consent (n=2) 
Withdrawn on the advice of 
invest_igator (=1) 
Figure 1.  CONSORT diagram—participant flow through the study.
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significant differences between groups in the secondary 
outcome measures and there were modest improvements 
from baseline in both groups that can be attributable to the 
exercise training.
It is possible that ACEi have no effect on physical func-
tion in older people without heart failure, but the evidence 
is contradictory. The Trial of Angiotensin-Converting 
Enzyme Inhibition and Novel Cardiovascular Risk Factors 
study compared 6 months of fosinopril versus placebo in 
a crossover study and found no change in SPPB (mean 
age 66 years) (26). In another study comparing ACEi with 
nifedipine (mean age 75 years), no significant differences 
in physical performance was seen between the two groups 
(27). However, in a small study of 36 older men with hyper-
tension, endurance increased in those receiving ACEi (28), 
and our previous randomized controlled trial in functionally 
impaired people showed that 20 weeks of ACEi treatment 
significantly improved 6MWD by 31.6 m compared with 
placebo and resulted in a clinically significant improvement 
in quality of life (6). In rodents, improvements in perfor-
mance with ACEi in combination with exercise but not with 
ACEi alone have been reported (29), but the evidence is not 
consistent (30,31).
Although it is possible that our previous study was spuri-
ously positive and the current study reflects the actual effect 
of ACEi on physical function in older people, other expla-
nations are possible. ACEi therapy may have very simi-
lar biological effects on physical function to 20 weeks of 
exercise training, and therefore, there is no added benefit of 
using these together. However, the wider benefits of exercise 
training, not achieved by ACEi therapy, should not be over-
looked. An adequate period of preconditioning with ACEi 
may be required to enhance the benefits of exercise. In the 
Lifestyle Interventions and Independence for Elders Pilot 
(LIFE-P) study, older people who were already taking ACEi 
for clinical reasons had a greater functional response to exer-
cise compared with those not taking ACEi (8). It is also pos-
sible that the degree of improvement possible in functionally 
impaired older people in only 20 weeks is fixed. Therefore, 
a longer study duration may be required to allow poten-
tial additive effects of ACEi to emerge. This, however, is 
unlikely given that most of the improvement we found with 
exercise was in the first 10 weeks. Finally, differences in the 
study population between the current study and our previous 
study may explain the different results. Although the mean 
age of participants was similar and the mean 6MWD was 
similar to our previous study, the current study may have 
attracted people who were interested in participating in exer-
cise, whereas our previous study could have attracted more 
sedentary people interested in an exercise mimic.
The strengths of our study are the double-blind rand-
omized controlled study design, the population of older 
people with functional impairment, and the range of out-
comes measuring different aspects of physical function. 
However, we did not measure body composition to char-
acterize participant phenotype in detail. A limitation is that 
the study included only two treatment arms. Inclusion of a 
control group (receiving no exercise or ACEi) and an ACEi-
only group would have allowed direct comparison of effects 
of ACEi and exercise training. However, potential bias due 
to difficulties of blinding exercise interventions would 
limit the value of such comparisons. A further limitation is 
that almost 27% discontinued study medication. This fig-
ure is similar to our previous study with ACEi where 27% 
dropped out suggesting that this is a real-life intention to 
Table 1. Summaries of Baseline Characteristics by Treatment Group
Perindopril (N = 86) Placebo (N = 84)
Age (years) 76.3 (7.3) 75.1 (6.2)
MMSE 27.8 (1.9) 27.7 (2.0)
Male 32 (37%) 39 (46%)
Use of walking aids 35 (41%) 35 (42%)
Deprivation quintile
 1 (most deprived) 25 (29%) 22 (26%)
 2 18 (21%) 12 (14%)
 3 9 (10%) 15 (18%)
 4 22 (26%) 20 (24%)
 5 (least deprived) 12 (14%) 15 (18%)
Medical history
 Osteoarthritis 45 (52%) 38 (45%)
 Chronic obstructive 
pulmonary disease
14 (16%) 8 (10%)
 Hypertension 31 (36%) 21 (25%)
 Angina 8 (9%) 6 (7%)
 Diabetes mellitus 6 (7%) 6 (7%)
 Peripheral arterial 
disease
1 (1%) 1 (1%)
 Atrial fibrillation 3 (3%) 7 (8%)
Medications
 Medications total 
number
5.2 (3.1) 5.1 (3.3)
 Beta blockers 14 (16%) 17 (20%)
 Calcium channel 
blockers
16 (19%) 15 (18%)
 Diuretics 23 (27%) 17 (20%)
 Analgesics 37 (43%) 41 (49%)
Measurements
 BMI (kg/m2) 28.0 (5.3) 29.2 (5.5)
 SBP (mmHg) 146.6 (18.8) 148.7 (19.6)
 DBP (mmHg) 79.8 (13.9) 79.7 (11.0)
 Creatinine (μmol/L) 75.2 (14.9) 79.4 (19.4)
 6MWD (m) 300.4 (101.1) 312.2 (97.5)
 Quadriceps strength 
(kg)
17.3 (10.7) 19.5 (11.6)
 Handgrip strength (kg) 19.5 (7.5) 20.6 (8.8)
 EQ-5D  0.68 (0.23)  0.68 (0.23)
 EQ-VAS 70.9 (16.2) 72.3 (15.7)
 SPPB 7.5 (1.7) 7.7 (2.0)
 FLP 851.5 (205.9) 867.5 (207.4)
Notes: 6MWD  =  6-minute walk distance; BMI  =  body mass index; 
DBP = diastolic blood pressure; EQ-5D = EuroQol 5D; EQ-VAS = EuroQol 
Visual Analogue Scale; FLP = Functional Limitation Profile; MMSE = Mini 
Mental State Examination; SBP  =  systolic blood pressure; SPPB = Short 
Physical Performance Battery.
Data are expressed as mean (SD) except where number of participants (%) 
are given.
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treat scenario in older people. Supervised progressive exer-
cise training was only provided for 10 weeks. The lack of 
improvement in physical function measures beyond 10 
weeks may be the result of poor adherence to the regimen 
during the second 10 weeks of unsupervised home-based 
exercise. However, the exercise ability of many partici-
pants had started to plateau by 10 weeks, and this phase of 
intervention for them was mostly targeted to maintaining 
improvements achieved.
In conclusion, concurrent ACEi therapy for 20 weeks 
did not enhance the response to progressive exercise train-
ing in older people with functional limitation. The body of 
evidence regarding the effect of ACEi on physical function 
in older people is contradictory and requires clarification. 
Participant differences in physical activity/ability levels may 
influence the results of studies. Given the individual and 
societal impact of functional impairment, it is vital to iden-
tify the phenotype of the older person most likely to benefit 
from ACEi therapy. A systematic review to synthesize the 
current evidence should guide further research strategies.
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